DIRS.INFO The most relevant business & tech news

☆ Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts
▼ + stars: | 2024-04-05 | by ( ) edition.cnn.com time to read: +3 min

Sanofi has reached an agreement in principle to settle 4,000 US lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday. Sanofi still faces about 20,000 lawsuits over Zantac in Delaware state court. That judge concluded that the opinions of the plaintiffs’ expert witnesses that Zantac can cause cancer were not supported by sound science. “We are pushing forward aggressively against GSK and Boehringer Ingelheim and are preparing for multiple trials in California state court this year,” Moore said. Lawsuits began piling up from people who said they developed cancer after taking Zantac.

Persons: Sanofi, “ Sanofi, Boehringer, Boehringer Ingelheim, Jennifer Moore, Brent Wisner, ” Moore, Zantac, ranitidine Organizations: Court, Sanofi, GSK, Pfizer, Boehringer, US Food and Drug Administration Locations: Delaware, Zantac, Wilmington, Florida, California

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Super Micro, Eli Lilly, Lyft, DoorDash, Disney & more
▼ + stars: | 2024-03-04 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

UBS upgrades Norfolk Southern to buy from neutral UBS said it sees margin improvement for the railroad. Goldman Sachs initiates Super Micro as neutral Goldman said the stock is an "AI winner" but that valuation is full right now. UBS reiterates Eli Lilly as buy UBS raised its price target on the stock to $910 per share from $810. UBS reiterates Nvidia as buy UBS said it's sticking with its buy rating after a series of investor meetings with the company." Argus upgrades New York Times to buy from neutral Argus said it sees revenue growth for the newspaper company. "

Persons: Morgan Stanley, Disney, Piper Sandler, Piper, Guggenheim, Baird, SQSP, Goldman Sachs, Goldman, Bernstein, Tesla, underperform Bernstein, Eli Lilly, Wells, Melius, Citi downgrades Ferrari, Jefferies, Evercore, it's, Rosenblatt, Snowflake, Slootman's Organizations: BROS, Guggenheim, GSK, UBS, Norfolk Southern, Micro, JPMorgan, Nvidia, Kyverna Therapeutics, FLT, UDR, Conservative, America Health, RBC, Apple, Citi, Ferrari, Jefferies, BP, Barclays, Barclays downgrades, ISI, Toast Inc, Bank of America, Ball Corp, of America, Broadcom, New York Times Locations: Norfolk, China, New

On a more positive note, Guggenheim upgraded GSK to buy thanks to strength across multiple product pipelines. Elsewhere, RBC upgraded Lyft to outperform, calling for a major rally ahead. Analyst Brad Erickson upgraded Lyft shares to outperform from sector perform, and raised his price target by $6 to $23, implying roughly 40.7% potential increase. — Pia Singh 6:10 a.m.: DoorDash upgraded by RBC on new partnerships potential, higher order growth RBC Capital Markets upgraded DoorDash to outperform from sector perform. Analyst Seamus Fernandez upgraded shares to buy from neutral and assigned a £20.31 price target, representing 21% upside to GSK's latest close.

Persons: Guggenheim, Wells Fargo, Timur Braziler, Braziler, — Pia Singh, Lyft, Brad Erickson, Erickson, Seamus Fernandez, Fernandez, Citi downgrades Ferrari, Ferrari, Harald Hendrikse, Fred Imbert Organizations: CNBC, Citi, Ferrari, GSK, RBC, Popular, RBC Capital Markets RBC Capital Markets, DASH, Capital Markets, Guggenheim Securities, drugmaker GSK, Guggenheim Locations: Wells Fargo, Puerto Rico, U.S, Wells, Shingrix, Arexvy, Milan

☆ Morningstar strategist names 3 under-the-radar picks for the current ‘stock picker market’
▼ + stars: | 2024-02-20 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +4 min

He said it's "always a stock picker's market," but that this is even more pertinent this year. Morningstar gives the company a five-star rating, and according to Sekera it has a healthy dividend yield and is trading at a 34% discount to Morningstar's fair value. Of the 23 analysts covering the stock, 11 give it a buy or overweight rating, while 12 have hold ratings. The average price target on the stock is $39.40, according to FactSet data, giving it potential upside of 13.2%. On GSK, Sekera noted that the London Stock Exchange-listed company is trading at a 27% discount.

Persons: David Sekera, Morningstar, Sekera, Kraft Heinz, it's Organizations: U.S . Federal, CNBC Pro, Kraft Heinz, Kraft, GSK, London Stock Exchange, Reuters Locations: United States

☆ GSK Confidentially Settles Another Zantac Lawsuit in California
▼ + stars: | 2024-02-01 | by ( Feb. | At A.M. | ) www.usnews.com time to read: +1 min

(Reuters) -GSK said on Thursday it agreed to confidentially settle one more lawsuit in California that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation. While NDMA can be present in low levels in food and water, research has found it causes cancer in larger amounts. The US Food and Drug Administration (FDA) in 2020 pulled Zantac and its generic versions off the market, triggering a wave of lawsuits. As of October, GSK still faced about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware. Analysts have estimated total settlement costs for GSK of around $5 billion, set to be realised in the first quarter of 2024.

Persons: drugmaker, Zantac, Eva Mathews, Savio D'Souza, Rashmi Organizations: Reuters, GSK, US Food and Drug Administration Locations: California, United States, Delaware . California, Bengaluru

☆ GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
▼ + stars: | 2023-11-30 | by ( Michele Gershberg | ) www.reuters.com time to read: +4 min

GSK had previously forecast 2023 sales for Arexvy between 900 million pounds and 1 billion pounds ($1.26 billion) following a strong U.S. launch. "We’re delighted with the start of our RSV vaccine," Walmsley said in a Reuters Newsmaker interview. The U.S. Food and Drug Administration (FDA) approved Arexvy for adults aged 60 years or older in May and GSK launched the vaccine in the U.S. later in the year. GSK made close to two-thirds of RSV doses given in the United States since early September, according to IQVIA data earlier this month. On Tuesday, rival Pfizer (PFE.N) said it was disappointed in the performance of its RSV shot Abrysvo compared with GSK.

Persons: Walmsley, GSK's, Emma Walmsley, We’re, David Denton, AstraZeneca's, commercialise Johnson, Ludwig Burger, Michael Erman, Josephine Mason, Kirsten Donovan, Elaine Hardcastle Organizations: GSK, Reuters, U.S . Food, Drug Administration, Pfizer, U.S, Thomson Locations: British, U.S, Europe, Japan, United States

☆ GSK lifts annual forecasts on strong launch of RSV vaccine
▼ + stars: | 2023-11-01 | by ( Eva Mathews | ) www.reuters.com time to read: +3 min

Arexvy, launched in the United States recently, recorded third quarter sales of 709 million pounds ($862 million), trouncing analysts' expectations of 358 million pounds, according to a company-compiled consensus. GSK accounts for close to two-thirds of RSV shots given in the United States since early September, according to IQVIA data. Full-year sales are seen between 900 million pounds and 1 billion pounds for the shot, GSK said. The company faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware and scheduled for trial starting January 2024. For the third quarter, Shingrix, the company's top-selling drug for shingles, generated 825 million pounds in sales.

Persons: Dado Ruvic, Abrysvo, Dani Saurymper, Emma Walmsley, Eva Mathews, Maggie Fick, Tomasz Janowski, Mark Potter Organizations: GSK, GlaxoSmithKline, REUTERS, stg, CVS, Pfizer, Pacific Asset Management, GSK's, Thomson Locations: London, United States, U.S, Europe, Japan, Delaware, Bengaluru

☆ GSK raises annual forecasts powered by strong Arexvy launch
▼ + stars: | 2023-11-01 | by ( ) www.reuters.com time to read: +2 min

Analysts expect the British drugmaker's RSV vaccine Arexvy to power future growth, amid worries about the strength of its pipeline of drugs in development and costly U.S. litigation over discontinued heartburn drug Zantac. Arexvy, launched in the United States recently, is expected to garner full-year sales of between 900 million pounds to 1 billion pounds ($1.22 billion), GSK said. For the third quarter, the shot recorded sales of 709 million pounds, trouncing analysts' expectations of 358 million pounds, according to a company-compiled consensus. Meanwhile, sales are seen to rise by 12% to 13% in 2023 compared with earlier expectations of 8% to 10%. For the reported quarter, sales of Shingrix, the company's top-selling drug to treat shingles, generated 825 million pounds, below market estimates of 868 million pounds.

Persons: Dado Ruvic, Eva Mathews, Subhranshu Sahu, Tomasz Janowski Organizations: GSK, GlaxoSmithKline, REUTERS, Thomson Locations: United States, Bengaluru

The trial for the Cantlay/Harper case, which was set to begin on Nov. 13, will now be dismissed, GSK said, adding it had also settled three remaining breast cancer cases in California related to the same drug. The latest settlements in California were related to cases due to go to trial in November, with a further set scheduled to begin in Delaware courts in January, GSK said. The company still faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware. GSK did not admit any liability and said it would vigorously defend itself in any other Zantac cases. In June, GSK agreed to settle a similar lawsuit in California.

Persons: Harper, Brendan McDermid, Morgan, Jeffries, Zantac, Boehringer Ingelheim, Eva Mathews, Maggie Fick, Nivedita Bhattacharjee, Bernadette Baum, Louise Heavens, Emelia Organizations: pare, Citi, GSK, Reuters, REUTERS, Barclays, Pfizer, Sanofi, FDA, Thomson Locations: California, British, Delaware, United States, Arexvy, California . California, Bengaluru, London

REUTERS/Brendan McDermid/Illustration/File Photo Acquire Licensing RightsOct 11 (Reuters) - GSK (GSK.L) on Wednesday said it would confidentially settle another lawsuit in California alleging its discontinued heartburn drug Zantac caused cancer, as the British drugmaker sought to end costly litigation. The latest settlements in California related to cases due to go to trial in November, with a further set scheduled to begin in Delaware courts in January, GSK said. The company still faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware. Late in June, the company agreed to settle a similar lawsuit with California resident James Goetz who alleged he developed bladder cancer after taking Zantac. The settlement could be read that GSK sees a risk that these Zantac cases are strong enough that the company might lose at trial, J.P Morgan added.

Persons: Brendan McDermid, Morgan, Harper, Zantac, Boehringer Ingelheim, James Goetz, J.P Morgan, Eva Mathews, Maggie Fick, Nivedita Bhattacharjee, Bernadette Baum Organizations: REUTERS, GSK, Citi, J.P, Pfizer, Sanofi, FDA, Thomson Locations: California, British, Delaware, United States, Bengaluru, London

☆ GSK raises $1.1 billion from Haleon stake sale
▼ + stars: | 2023-10-06 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Dado Ruvic/Illustration Acquire Licensing RightsOct 6 (Reuters) - British drugmaker GSK (GSK.L) on Friday said it raised 885.6 million pounds ($1.08 billion) from a discounted stake sale in Haleon (HLN.L), cutting its shareholding to 7.4% in the world's largest standalone consumer healthcare firm. The sale of 270 million shares at 328 pence apiece, represented a discount of about 2.5% to Haleon's last close of 336.25 pence on Thursday. Shares in Haleon were down 1.2% while GSK was marginally up 0.4% at 0800 GMT. Pfizer, which holds a 32% stake in Haleon, said in May it plans to cut its ownership in a "slow and methodical" manner within months. The British drugmaker and Pfizer have agreed to not sell any further Haleon shares for 60 days from the settlement of placing.

Persons: Dado Ruvic, Emma Walmsley, Prerna Bedi, Sonia Cheema, Elaine Hardcastle Organizations: GSK, GlaxoSmithKline, REUTERS, British, AstraZeneca, London Stock Exchange, Pfizer, Thomson Locations: Haleon, British, Bengaluru

GSK reckons the spin-off has allowed the company to sharpen its focus on vaccines and infectious diseases and with $7 billion generated by the Haleon spin-off, it can fund deals to bolster a lacklustre drug pipeline. The company also reported an adjusted profit of 38.8 pence per share for the quarter, on sales of about 7.18 billion pounds ($9.26 billion). Analysts were expecting a profit of 34.7 pence per share on sales of about 6.77 billion pounds, according to company-compiled consensus estimates. Sales of Shingrix, the company's top-selling drug, generated 880 million pounds, beating analyst estimates of 872 million pounds. Sales of HIV treatments generated 1.58 billion in the quarter, ahead of the company-compiled consensus of about 1.5 billion pounds in the quarter.

Persons: Zantac, Emma Walmsley, Walmsley, Markus Manns, Dani Saurymper, Maggie Fick, Radhika Anilkumar, Janane Venkatraman, Savio D'Souza, Josephine Mason Organizations: GSK, British, Analysts, U.S, Union Investment, Pacific Asset Management, Thomson Locations: London, Bengaluru

The STOXX 600 (.STOXX) index closed 0.3% lower after data showed euro zone business growth stalled this month as the downturn in manufacturing deepened. "A hike was fully expected, but the magnitude of the rise surprised most," said RBC Brewin Dolphin’s head of asset allocation, Paul Danis. Germany's DAX index (.GDAXI) shed 1.0%, leading losses among regional peers as shares of Siemens Energy (ENR1n.DE) sank 37.3%. DATA DIGESTWhile euro zone business growth stalled in June, a separate reading showed German business activity slowed notably this month. French business activity contracted this month for the first time in five months, data showed.

Persons: Germany's DAX, Paul Danis, DAX, Clemente De Lucia, Shreyashi Sanyal, Bansari, Eileen Soreng, Jonathan Oatis Organizations: Siemens Energy, GSK, Bank of England, Norges Bank, Swiss National Bank, Investors, RBC, Bank, Siemens, Deutsche Bank Research, Thomson Locations: U.S, Stockholm, Helsinki, Bengaluru

GSK on Friday said the settlement reflected its desire to avoid distraction related to protracted litigation in this case. It did not admit any liability and said it would vigorously defend itself in any other Zantac cases. The trial was due to start on July 24, the first test of how Zantac cancer claims would fare before a jury. Lucy Coutts, investment director at wealth management firm JM Finn, which holds GSK shares, said the Goetz settlement could create a precedent to settle other cases. "It also removes the distraction of any protracted litigation as the company must focus on its future pipeline which is where value will be created for shareholders," she said.

Persons: drugmaker, James Goetz, Emily Field, Lucy Coutts, JM Finn, Goetz, Dado Ruvic, Boehringer Ingelheim, Zantac, Natalie Grover, Eva Mathews, Dhanya Ann Thoppil, Barbara Lewis Organizations: GSK, Barclays, GlaxoSmithKline, REUTERS, Pfizer, Sanofi, Companies, Bank of America, FDA, Thomson Locations: U.S, British, California, Delaware, London, Bengaluru

☆ London stocks open lower on recession fears; homebuilders worst hit
▼ + stars: | 2023-06-23 | by ( ) www.reuters.com time to read: +1 min

SummarySummary Companies FTSE 100 down 0.2%, FTSE 250 off 0.4%June 23 (Reuters) - UK's benchmark indexes extended their slide on Friday, led by a decline in homebuilders, as investors' concerns over recession heightened following the Bank of England's outsized interest rate hike. The benchmark FTSE 100 (.FTSE) was down 0.2% at 0706 GMT, while the FTSE 250 (.FTMC) mid-cap index lost 0.4%. Both indexes were on track for their worst weekly drop since the U.S. banking turmoil in March. Retail sales, however, unexpectedly rose in May, suggesting most consumers were coping with rigid inflation's impact on their spending power. Reporting by Ankika Biswas in Bengaluru; Editing by Sherry Jacob-PhillipsOur Standards: The Thomson Reuters Trust Principles.

Persons: BoE, Ankika Biswas, Sherry Jacob, Phillips Organizations: Bank of England's, Federal Reserve, GSK, Thomson Locations: homebuilders, U.S, Norway, Switzerland, Bengaluru

CompaniesCompanies Law Firms Pfizer Inc FollowSanofi SA FollowJune 23 (Reuters) - GSK (GSK.L) reached a settlement with a U.S. citizen who alleged its discontinued heartburn drug Zantac caused cancer, the British pharmaceutical giant said on Friday, preventing the first such lawsuit from going to trial. The case, brought by California resident James Goetz in Alameda County Superior Court, was to go to trial on July 24 and would have been the first test of how Zantac cancer claims fared before a jury. The parties reached a confidential settlement and the trial will be dismissed, GSK said. Originally marketed by a forerunner of GSK Plc, Zantac was later sold successively to Pfizer (PFE.N), Boehringer Ingelheim and finally Sanofi (SASY.PA). Last month, a Canadian court dismissed a proposed class action against Zantac over increased cancer risk.

Persons: James Goetz, Zantac, Boehringer Ingelheim, GSK's, Eva Mathews, Dhanya Ann Thoppil, Barbara Lewis Organizations: Law, Pfizer, Sanofi, GSK, Alameda County Superior Court, GSK Plc, U.S . Food, Drug Administration, Thomson Locations: California, Alameda County, U.S, Zantac, Bengaluru

☆ Stocks making the biggest moves midday: Starbucks, CarMax, Virgin Galactic and more
▼ + stars: | 2023-06-23 | by ( Samantha Subin | ) www.cnbc.com time to read: +2 min

A view of the Starbucks vending van during its debut in Hangzhou, the capital of China's Zhejiang province, June 7, 2022. Starbucks — Starbucks shares lost nearly 2.5% after a union representing workers said strikes are slated to begin Friday in response to claims the coffee shop chain is not allowing Pride decorations at cafes. More than 150 stores, and about 3,500 workers, plan to join the strike occurring over the next week, the union said. CarMax — The used-car retailer popped 10% after beating the consensus estimate of analysts for its first-quarter revenue. Virgin Galactic — Virgin Galactic shed 18% after announcing a $300 million capital raise via a common stock offering.

Persons: CarMax, Armour, Wells Fargo, TD Cowen, Morgan Stanley, Evotec, — CNBC's Michelle Fox, Alex Harring, Jesse Pound Organizations: Starbucks, StreetAccount ., Galactic, Deutsche Bank, Accenture —, Accenture, GSK — U.S, GSK Locations: Hangzhou, China's Zhejiang province, North America, Germany

☆ Sanofi says arbitration court rejects Boehringer's Zantac claims
▼ + stars: | 2023-06-20 | by ( Ludwig Burger | ) www.reuters.com time to read: +1 min

FRANKFURT, June 20 (Reuters) - Sanofi (SASY.PA) said on Tuesday that the International Chamber of Commerce rejected rival drugmaker Boehringer Ingelheim's (BI) claims to be indemnified by Sanofi in cancer lawsuits linked to heartburn drug Zantac in the United States. Shares in France's Sanofi, which added that the decision cannot be appealed, gained 2.4% shortly after the 0700 GMT market open, reaching a three-week high. Sanofi and Boehringer had sought arbitration to determine whether liability in lawsuits was transferred to the French group after it acquired the marketing rights from Boehringer in a 2017 deal. Sanofi reiterated that it regarded its defence of the underlying litigation as very strong. "There is no reliable scientific evidence that Zantac causes the alleged injuries in the cases brought against GSK, Pfizer, BI, Sanofi, and others in the U.S. litigation," the company said.

Persons: drugmaker Boehringer, Boehringer, Sanofi, Ludwig Burger, Kirsten Donovan, Emma Rumney Organizations: Sanofi, International Chamber of Commerce, GSK, Pfizer, BI, Thomson Locations: FRANKFURT, United States, Boehringer, U.S

Germany's DAX index (.GDAXI) fell 0.3% by 0750 GMT, retreating farther from a record high hit on Friday. The continent-wide STOXX 600 index (.STOXX) edged 0.1% lower. The chemicals index (.SX4P) slid 1.7%, leading sectoral declines. London's FTSE 100 index (.FTSE) rose 0.2%. Reporting by Shreyashi Sanyal in Bengaluru; editing by Eileen SorengOur Standards: The Thomson Reuters Trust Principles.

Persons: DAX, Boehringer's Zantac, Stuart Cole, drugmaker, Boehringer, Jerome Powell, Shreyashi Sanyal, Eileen Soreng Organizations: Europe Sanofi, Equiti, People's Bank of China, Sanofi, International Chamber of Commerce, Global Auto Holdings, Bank of, Investors, . Federal, Thomson Locations: Europe, China, United States, British, Bengaluru

LONDON, April 26 (Reuters) - GSK (GSK.L) began 2023 with a quarterly performance that beat analyst expectations and extended a series of positive results following strong sales of its roster of vaccines as well as HIV and respiratory medicines. Investors are also concerned about the company's long-term prospects, given the pending loss of patent protection of one of GSK's HIV compounds and setbacks in its marketed oncology portfolio. GSK is also relying in part on its potential blockbuster vaccine for RSV, which leads to thousands of hospitalisations and deaths each year. It anticipates launching the vaccine later this year in the U.S. and Europe, pending regulatory approval, as does rival Pfizer (PFE.N). ($1 = 0.8039 pounds)Reporting by Maggie Fick and Natalie Grover in London, Editing by Louise HeavensOur Standards: The Thomson Reuters Trust Principles.

☆ J&J carves itself up at a discount
▼ + stars: | 2023-04-24 | by ( Robert Cyran | ) www.reuters.com time to read: +4 min

NEW YORK, April 24 (Reuters Breakingviews) - Johnson & Johnson (JNJ.N) is paying a price to dismember itself. That’s nearly a 20% discount to rival Haleon (HLN.L), the consumer business spun off from GSK (GSK.L) last year. The drug and surgical businesses remaining with J&J are higher margin and potentially faster-growing, so perhaps the two firms will appeal to different sets of investors. Even the unknown at the former J&J company is better than the unknown elsewhere. Johnson & Johnson is in the midst of trying to settle tens of thousands of lawsuits that its talc-based products caused cancer.

The trial will be the first test of how Zantac cancer claims will fare before a jury. GSK said in a statement it disagreed with the ruling and would defend the case at trial. Originally marketed by a forerunner of GSK, it was later sold successively to Pfizer (PFE.N), Boehringer Ingelheim and finally Sanofi (SASY.PA). While NDMA is found in low levels in food and water, it is known to cause cancer in larger amounts. Analysts said it was not surprising that Grillo ruled differently from the federal court because California's courts are known to be friendlier to plaintiffs.

☆ Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data
▼ + stars: | 2023-03-23 | by ( Ludwig Burger Jubabu | Ludwig Burger | ) www.reuters.com time to read: +4 min

Sanofi and Regeneron said in a statement on Thursday a Phase III trial involving 939 current or former smokers also showed improvements in lung function, quality of life and COPD respiratory symptoms. JP Morgan analyst Richard Vosser said the trial update had "blow-out data" in store for investors, and that market consensus for 2027 Dupixent sales of 15.7 billion euros would likely be topped-up by between 1 and 2 billion euros. The anti-inflammatory drug accounted for 8.3 billion euros, or more than 19% of the French group's overall sales of 43 billion euros, last year. Sanofi reports combined global Dupixent sales from its alliance with Regeneron. Sanofi and Regeneron on Tuesday announced the European Commission had approved Dupixent to treat severe atopic dermatitis in young children.

☆ A Legal Shakedown Exposed
▼ + stars: | 2023-02-17 | by ( The Editorial Board | ) www.wsj.com time to read: 1 min

Claims by the small laboratory company, Valisure LLC, that popular consumer products contain cancer-causing chemicals have generated headlines, but don’t believe everything you read. A federal judge recently exposed some of Valisure’s dubious scientific methods, and now there’s new evidence of how the firm uses its claims as part of its business model. The press has amplified Valisure’s claims that sunscreens, antiperspirants, dry shampoos, hand sanitizers and the heartburn medication Zantac contain dangerous levels of cancer-causing chemicals. In 2022 Valisure said 70% of dry shampoo that it tested contains benzene, often in amounts that far exceed what is considered the safe daily limit.

REUTERS/Brendan McDermid/IllustrationFeb 16 (Reuters) - GSK Plc (GSK.L) is expected to urge a California judge on Thursday to limit what expert testimony jurors can hear in the first trial over claims that the company's heartburn drug Zantac caused cancer. The trial, scheduled to begin Feb. 27 before Alameda County Superior Court Judge Evelio Grillo, will offer the first test of how Zantac cancer claims may fare in state courts. The plaintiff in the upcoming trial, James Goetz, says he developed bladder cancer from taking Zantac sold by British drugmaker GSK. Lawsuits began piling up soon after the recalls began from people who said they developed cancer after taking Zantac. Cases have been filed linking Zantac to at least 10 types of cancer.

Search resuls for: "Zantac"

25 mentions found